<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Management | Management | Obesity | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers the management of a person who is overweight or obese."/><meta data-react-helmet="true" property="og:description" content="Covers the management of a person who is overweight or obese."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/obesity/management/management/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Management | Management | Obesity | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/obesity/management/management/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Obesity</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Management</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/obesity/","name":"Obesity"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/obesity/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Management"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Obesity: </span><span>Scenario: Management</span></h1><p class="page-header__lead"><span>Last revised in December 2017</span></p></div><p class="visually-hidden">Covers the management of a person who is overweight or obese.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Obesity chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Diagnosis"><a aria-current="false" href="../../diagnosis/index.html"><span class="stacked-nav__content-wrapper">Diagnosis</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Management"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Management</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Prescribing information"><a aria-current="false" href="../../prescribing-information/index.html"><span class="stacked-nav__content-wrapper">Prescribing information</span></a></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#general-principles-of-care">General principles of care</a><ol aria-label="Sections within General principles of care" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-928">Basis for recommendation</a></li></ol></li><li><a href="index.html#assessing-a-person-who-is-overweight-or-obese">Assessing a person who is overweight or obese</a><ol aria-label="Sections within Assessing a person who is overweight or obese" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-c38">Basis for recommendation</a></li></ol></li><li><a href="index.html#overview-of-management">Overview of management</a><ol aria-label="Sections within Overview of management" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#behavioural-interventions">Behavioural interventions</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-77c">Basis for recommendation</a></li></ol></li><li><a href="index.html#dietary-advice">Dietary advice</a><ol aria-label="Sections within Dietary advice" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-8d3">Basis for recommendation</a></li></ol></li><li><a href="index.html#advice-on-physical-activity">Advice on physical activity</a><ol aria-label="Sections within Advice on physical activity" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-b88">Basis for recommendation</a></li></ol></li><li><a href="index.html#drug-treatment">Drug treatment</a><ol aria-label="Sections within Drug treatment" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-9b2">Basis for recommendation</a></li></ol></li><li><a href="index.html#bariatric-surgery">Bariatric surgery</a><ol aria-label="Sections within Bariatric surgery" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-e36">Basis for recommendation</a></li></ol></li><li><a href="index.html#referral">Referral</a><ol aria-label="Sections within Referral" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-2dc">Basis for recommendation</a></li></ol></li><li><a href="index.html#advice-support">Advice and support</a><ol aria-label="Sections within Advice and support" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-822">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="management" class="ChapterBody-module--wrapper--2HCfk "><h2 id="management" class="visually-hidden">Scenario: Management</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2b5e2f66-6ce0-4c72-ab5b-61ba29fb31f7 --><!-- begin field 7cb5fe6f-3693-4f8d-8309-acd900ab9478 --><p>From age 18 years onwards.</p><!-- end field 7cb5fe6f-3693-4f8d-8309-acd900ab9478 --><!-- end item 2b5e2f66-6ce0-4c72-ab5b-61ba29fb31f7 --></div><section aria-labelledby="general-principles-of-care" class="ChapterBody-module--wrapper--2HCfk "><h3 id="general-principles-of-care">What are the general principles of managing a person who is overweight or obese? </h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 86aefabc-cb82-4c5c-baba-d42ac6a660a3 --><!-- begin field e99085f5-b972-41ad-a675-e27b24962e21 --><ul><li><strong>Approach the subject of weight carefully because people who are overweight or obese may be sensitive about discussing it, or feel that their presenting problem is being overlooked. </strong><ul><li>The Public Health England (PHE) guidance on <a href="https://www.gov.uk/government/publications/adult-weight-management-a-guide-to-brief-interventions" data-hyperlink-id="ac521900-cb02-40a1-b78e-a93100b3dcb8">Adult weight management: a guide to brief interventions</a> includes a step-by-step guide to brief interventions with adults for healthcare professionals, which offers advice on consultations with overweight and obese people regarding weight loss. </li><li>Ensure there is adequate time in the consultation to provide information and answer questions. </li><li>Encourage the person's partner or spouse to support any weight management programme, as they can influence both the person's decision to seek treatment and their adherence to treatment recommendations or lifestyle changes.</li></ul></li><li><strong><a class="topic-reference internal-reference" href="index.html#assessing-a-person-who-is-overweight-or-obese">Assess</a>:</strong><ul><li>The person's willingness and motivation to lose weight.</li><li>The person's feelings about being overweight (for example beliefs and previous attempts to lose weight) and their confidence in making changes. </li><li>For underlying causes and comorbidities (for example medical problems, medication, and psychological and social factors).</li><li>The person's risk of developing complications of obesity.</li></ul></li><li><strong>Discuss (and agree on) the choice of interventions for weight management with the person.</strong><ul><li><a class="topic-reference internal-reference" href="index.html#overview-of-management">Multicomponent interventions</a>  are the treatment of choice.<ul><li>Ensure weight management programmes include behaviour change strategies to increase people's physical activity levels or decrease inactivity, improve eating behaviour and the quality of the person's diet, and reduce energy intake. </li><li>Drug treatment and/or surgery may be required in some cases. </li></ul></li><li>Tailor the components of the planned weight management programme to the person's preferences, initial fitness, health status, and lifestyle.</li><li>When deciding on treatment type (and intensity), consider the person's:<ul><li>Degree of overweight or obesity.</li><li><a class="topic-reference internal-reference" href="index.html#assessing-a-person-who-is-overweight-or-obese">Level of risk</a> (using body mass index and waist circumference, if appropriate). </li><li>Potential for <a class="topic-reference internal-reference" href="../../background-information/prognosis/index.html">health benefits</a>  from weight loss.</li><li>Comorbidities.</li><li>Social circumstances.</li><li>Initial fitness.</li><li>Previous treatments.</li></ul></li></ul></li></ul><!-- end field e99085f5-b972-41ad-a675-e27b24962e21 --><!-- end item 86aefabc-cb82-4c5c-baba-d42ac6a660a3 --></div><section aria-labelledby="basis-for-recommendation-928" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-928">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 928490e9-9427-447c-8cc8-a793ddec12e4 --><!-- begin field 2f396b1e-95e8-49da-b98b-b9ab55fb6e07 --><p>The recommendations on the management of overweight and obesity are based largely on the National Institute for Health and Care Excellence (NICE) guideline <em>Obesity: identification, assessment and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>]<em> </em>(which replaces section 1.2 in the NICE guideline on <em>Obesity Prevention</em><em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2006a</a>]). For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/cg189/evidence" data-hyperlink-id="1f3db694-74c7-4407-88a3-a93100c5294b">full NICE guideline</a>. These recommendations are generally in line with recommendations (and expert opinion) in <a class="topic-reference internal-reference" href="../../have-i-got-the-right-topic/index.html">related NICE guidelines</a>, the Scottish Intercollegiate Guidelines Network (SIGN) guideline on <em>Management of obesity</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2010</a>], and the NHS document <em>Healthy weight, healthy lives: a toolkit for developing local strategies</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FPH, 2008</a>]; several European guidelines, including <em>Pharmacological management of obesity: an endocrine Society clinical practice guideline</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Apovian, 2015</a>], <em>An EASO position statement on multidisciplinary obesity management in adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2014</a>], and the <em>European Guidelines for Obesity Management in Adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>]; international guidelines, including the A<em>merican Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Garvey, 2016</a>], <em>Position of the Academy of Nutrition and Dietetics: Interventions for the Treatment of Overweight and Obesity in Adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Raynor, 2016</a>], <em>Assessment and Lifestyle Management of Patients With Obesity</em> (clinical recommendations from systematic reviews) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kushner, 2014</a>], <em>2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Jensen, 2014</a>], and <em>Recommendations for prevention of weight gain and use of behavioural and pharmacologic interventions to manage overweight and obesity in adults in primary care </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Brauer, 2015</a>]; the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 74, 2017</a>]; and review articles on obesity [<a class="bibliography-reference internal-reference" href="../../references/index.html">Skolnik, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Bray, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">BMJ, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Erlandson, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">McGowan, 2016</a>]. </p><ul><li>NICE focuses on the concept of patient-centered care, and advises that the choice of interventions for weight management should be discussed and agreed with the person. </li><li>A multidisciplinary approach in the management of people with obesity is necessary across all levels of care.<ul><li>The BNF highlights that people who are overweight or obese should be encouraged to engage in a sustainable weight management programme which includes strategies to change behaviour, increase physical activity, and improve diet and eating behaviour [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 74, 2017</a>].</li><li>The Academy of Nutrition and Dietetics states that successful treatment of overweight and obesity in adults requires adoption and maintenance of lifestyle behaviours contributing to both dietary intake and physical activity. Since these behaviours are influenced by many factors, interventions incorporating more than one level of the socioecological model and addressing several key factors in each level may be more successful than interventions targeting any one level and factor alone [<a class="bibliography-reference internal-reference" href="../../references/index.html">Raynor, 2016</a>].</li></ul></li><li>NICE recommends that the person's partner or spouse should be encouraged to support any weight management programme as it is likely to promote success<em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>]<em>. </em>Expert opinion in a review article is that family members can influence both the person's decision to seek treatment and their adherence to treatment recommendations or lifestyle changes [<a class="bibliography-reference internal-reference" href="../../references/index.html">McGowan, 2016</a>].</li></ul><!-- end field 2f396b1e-95e8-49da-b98b-b9ab55fb6e07 --><!-- end item 928490e9-9427-447c-8cc8-a793ddec12e4 --></div></section></section><section aria-labelledby="assessing-a-person-who-is-overweight-or-obese" class="ChapterBody-module--wrapper--2HCfk "><h3 id="assessing-a-person-who-is-overweight-or-obese">How should I assess a person who is overweight or obese?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f5e45b35-2b9c-4ad2-82ba-a84b0077ebbb --><!-- begin field 2979bee1-a82c-4986-9615-a84b0077ed16 --><p><strong>Assess the person's willingness and motivation to lose weight. </strong></p><ul><li>Recognise that surprise, anger, denial, or disbelief about their health situation may diminish people's ability or willingness to change. Stress that obesity is a clinical term with specific health implications, rather than a question of how people look; this may reduce any negative feelings.</li><li>Be aware that people from certain ethnic and socioeconomic backgrounds may be at greater risk of obesity, and may have different beliefs about what is a healthy weight and different attitudes towards weight management.</li><li><strong>Questions which may help to clarify a person's readiness to lose weight include:</strong><ul><li>Are you concerned about your weight?</li><li>How important is it for you to lose weight at the moment?</li><li>Do you believe that you could lose weight?</li><li>What would have to change in your life for you to be able to tackle your weight?</li><li>Is your weight affecting your life in any way at the moment?</li></ul></li><li><strong>If the person (or their family/carers) declines intervention or does not feel it is the right time for them to take action:</strong><ul><li>Explain that advice and support will be available in the future.</li><li>Provide contact details so that the person can get in touch when they are ready. </li></ul></li></ul><p><strong>Assess the person's feelings about being overweight (for example beliefs and previous attempts to lose weight) and their confidence in making changes. </strong></p><ul><li>Barriers to lifestyle change include:<ul><li>Lack of knowledge about food and how diet and exercise affect health.</li><li>Cost and availability of healthy foods and opportunity for exercise.</li><li>Safety concerns.</li><li>Lack of time.</li><li>Personal tastes.</li><li>Views of family and community members.</li><li>Low levels of fitness, or disability.</li><li>Low self-esteem and lack of assertiveness.</li></ul></li><li>Enquire about the role of family and care workers in supporting people with learning disabilities to make lifestyle changes. </li></ul><p><strong>Assess for <a class="topic-reference internal-reference" href="../../background-information/causes-risk-factors/index.html">underlying causes</a> and comorbidities (for example medical problems, medication, and psychological or social factors).</strong></p><ul><li>Take a detailed history, including: <ul><li>Medical history:<ul><li>Enquire about <a class="topic-reference internal-reference" href="../../background-information/causes-risk-factors/index.html">medical conditions</a> that can contribute to overweight and obesity, or <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a> that may arise as a result of excess weight.</li><li>Pay particular attention to symptoms of comorbidities that might not be recognized (for example sleep apnoea).</li><li><strong>Manage any comorbidities at the time they are identified. Do not delay treatment until the person has lost weight.</strong></li></ul></li><li>Family history (for example family history of overweight and obesity, and comorbidities).</li><li>Drug history — identify <a class="topic-reference internal-reference" href="../../background-information/causes-risk-factors/index.html">medication(s)</a> that might cause weight gain.</li><li>Social history (for example lifestyle, diet, exercise, alcohol and smoking, and work and leisure activities).</li></ul></li><li>Examine the person.<ul><li>Check blood pressure using an appropriately sized arm cuff.</li></ul></li><li>Arrange appropriate investigations.<ul><li>Check blood glucose and lipid profile, preferably on a fasting sample.</li><li>Arrange other investigations as directed by the person's history and examination (for example liver function tests and thyroid function tests).</li><li>Initial investigations can be useful as a baseline for future measurements.</li></ul></li><li>Give people and their families and/or carers information on the reasons for any tests done, how the tests are done, and their results and meaning. If necessary, offer another consultation to fully discuss test results and/or treatment options. </li></ul><p><strong>Assess the person's risk of developing <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a> of obesity.</strong></p><ul><li>Ask about family history of diabetes (including gestational diabetes) and coronary heart disease.</li><li>Using the person's body mass index (BMI), waist circumference (where applicable), and the information in Table 3. assess whether the person is at increased risk of cardiovascular and metabolic complications. <ul><li>Explain why excess weight can be problematic in terms of comorbidities and the chance of developing complications.</li><li>Discuss why gaining more weight may increase risks to health.</li><li>Make the person aware of the <a class="topic-reference internal-reference" href="../../background-information/prognosis/index.html">benefits</a> of modest weight loss with regard to comorbidities and disease risk, particularly if they are obese.</li></ul></li></ul><p><strong>Table 3.</strong> Classification of cardiovascular and metabolic disease risk by waist circumference in people who are overweight or in obesity class I.</p><table data-table-id="aafdda43-6719-4048-8bbf-acce014c9186"><thead><tr><th colspan="1">Body mass index (BMI)*</th><th colspan="3">Waist circumference</th></tr></thead><tbody><tr><td colspan="1"> </td><td colspan="1"><strong>Low</strong><sup>§</sup></td><td colspan="1"><strong>High</strong><sup>§</sup></td><td colspan="1"><strong>Very high</strong><sup>§</sup></td></tr><tr><td colspan="1">Overweight (BMI 25–29.9)</td><td colspan="1">No increased risk</td><td colspan="1">Increased risk</td><td colspan="1">High risk</td></tr><tr><td colspan="1">Obesity I (BMI 30–34.9)</td><td colspan="1">Increased risk</td><td colspan="1">High risk</td><td colspan="1">Very high risk</td></tr><tr><td colspan="4"><p>* Some population groups (for example Asian people and older people) have cormobidity risk factors that are of concern at different BMIs (lower for Asian people and higher for older people). Use clinical judgement when considering risk factors in these groups, even in people not <a class="topic-reference internal-reference" href="../../background-information/definition/index.html">classified</a> as overweight or obese. People with BMI of 35 kg/m<sup>2 </sup>or more are at very high risk, regardless of waist circumference.                                 </p><p><sup>§ </sup>For men, waist circumference less than 94 cm (37 inches) is low, 94–102 cm (37–40 inches is high, and greater than 102 cm (approximately 40 inches) is very high. For women, waist circumference less than 80 cm (31.5 inches) is low, 80–88 cm (31.5–34.5 inches) is high, and greater than 88 cm (approximately 34.5 inches) is very high.</p></td></tr><tr><td colspan="4"><p><strong>Data from:</strong> [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2010</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>]</p></td></tr></tbody></table><!-- end field 2979bee1-a82c-4986-9615-a84b0077ed16 --><!-- end item f5e45b35-2b9c-4ad2-82ba-a84b0077ebbb --></div><section aria-labelledby="basis-for-recommendation-c38" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-c38">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c3863663-d563-45a7-a5db-a84b0077ed1d --><!-- begin field 282e658d-a160-47ba-a626-a84b0077ed1d --><p>The recommendations on the management of overweight and obesity are based largely on the National Institute for Health and Care Excellence (NICE) guideline <em>Obesity: identification, assessment and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>]<em> </em>(which replaces section 1.2 in the NICE guideline on <em>Obesity Prevention</em><em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2006a</a>]). For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/cg189/evidence" data-hyperlink-id="f4f19175-c51a-40b4-b581-a93100c54e30">full NICE guideline</a>. These recommendations are generally in line with recommendations (and expert opinion) in <a class="topic-reference internal-reference" href="../../have-i-got-the-right-topic/index.html">related NICE guidelines</a>, the Scottish Intercollegiate Guidelines Network (SIGN) guideline on <em>Management of obesity</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2010</a>], and the NHS document <em>Healthy weight, healthy lives: a toolkit for developing local strategies</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FPH, 2008</a>]; several European guidelines, including <em>Pharmacological management of obesity: an endocrine Society clinical practice guideline</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Apovian, 2015</a>], <em>An EASO position statement on multidisciplinary obesity management in adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2014</a>], and the <em>European Guidelines for Obesity Management in Adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>]; international guidelines, including the A<em>merican Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Garvey, 2016</a>], <em>Position of the Academy of Nutrition and Dietetics: Interventions for the Treatment of Overweight and Obesity in Adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Raynor, 2016</a>], <em>Assessment and Lifestyle Management of Patients With Obesity</em> (clinical recommendations from systematic reviews) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kushner, 2014</a>], <em>2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Jensen, 2014</a>], and <em>Recommendations for prevention of weight gain and use of behavioural and pharmacologic interventions to manage overweight and obesity in adults in primary care </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Brauer, 2015</a>]; the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 74, 2017</a>]; and review articles on obesity [<a class="bibliography-reference internal-reference" href="../../references/index.html">Skolnik, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Bray, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">BMJ, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Erlandson, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">McGowan, 2016</a>]. </p><ul><li>Expert opinion in the <em>European Guidelines for Obesity Management in Adults </em>is that [<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>]:<ul><li>Obesity management may reduce the need for drug treatment of comorbidities; therefore, a comprehensive history, physical examination, and laboratory assessment relevant to the person's obesity should be obtained.</li><li>In addition to emphasising realistic weight loss (to achieve a reduction in health risks) and advising on prevention of weight regain, appropriate goals of weight management should include management of comorbidities and improving the person's quality of life.</li></ul></li></ul><!-- end field 282e658d-a160-47ba-a626-a84b0077ed1d --><!-- end item c3863663-d563-45a7-a5db-a84b0077ed1d --></div></section></section><section aria-labelledby="overview-of-management" class="ChapterBody-module--wrapper--2HCfk "><h3 id="overview-of-management">How should I manage a person who is overweight or obese?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 47723b3b-087e-4a2a-b1e5-218552b669d9 --><!-- begin field f9ccc573-a650-4825-95d3-0bc546939708 --><ul><li><strong>For people with a body mass index (BMI) of 25–29.9 kg/m<sup>2</sup> (overweight):</strong><ul><li><strong>And low w</strong><strong>aist circumference (less than 80 cm for women or less than 94 cm for men):</strong> offer <a class="topic-reference internal-reference" href="index.html#advice-support">general advice</a>  on healthy weight and lifestyle.</li><li><strong>And large w</strong><strong>aist circumference (80 cm or more for women or 94 cm or more for men):</strong> offer structured advice regarding <a class="topic-reference internal-reference" href="index.html#advice-on-physical-activity">physical activity</a> and <a class="topic-reference internal-reference" href="index.html#dietary-advice">diet</a>. Consider the use of <a class="topic-reference internal-reference" href="index.html#behavioural-interventions">behavioural interventions</a> to achieve this aim.</li><li>Consider starting <a class="topic-reference internal-reference" href="index.html#drug-treatment">drug treatment</a> in overweight people with a BMI of 27 kg/m<sup>2 </sup>with<em> </em>associated risk factors (such as type 2 diabetes, hypertension, or dyslipidaemia). </li><li><strong>Be aware that drug treatment for people with obesity or overweight should:</strong><ul><li>Only be considered once dietary and physical activity interventions have been evaluated.</li><li>Form part of an integrated approach to weight management, which should include advice, support, counselling on diet and physical activity, and behavioural strategies.</li></ul></li><li>Consider the need for <a class="topic-reference internal-reference" href="index.html#referral">referral</a> to weight management services (tier 2 services) or specialist obesity services (tier 3 services). <ul><li>The National Institute for Health and Care Excellence (NICE) guideline on <a href="https://www.nice.org.uk/guidance/ph53/chapter/6-Related-NICE-guidance" data-hyperlink-id="f34d7430-9437-4bca-b659-a93100b3227f">Weight management: lifestyle services for overweight or obese adults</a> covers multi-component lifestyle weight management services including programmes, courses, clubs, or groups provided by the public, private, and voluntary sector. </li></ul></li></ul></li><li><strong>For people with a BMI of 30–34.9 kg/m<sup>2</sup> (obesity I):</strong><ul><li>Offer structured advice regarding <a class="topic-reference internal-reference" href="index.html#advice-on-physical-activity">physical activity</a> and <a class="topic-reference internal-reference" href="index.html#dietary-advice">diet</a>. Consider the use of <a class="topic-reference internal-reference" href="index.html#behavioural-interventions">behavioural interventions</a> to achieve this aim.</li><li>Consider starting <a class="topic-reference internal-reference" href="index.html#drug-treatment">drug treatment</a> in people with associated risk factors (such as type 2 diabetes, hypertension, or dyslipidaemia).</li><li>Consider the need for <a class="topic-reference internal-reference" href="index.html#referral">referral</a>  for weight management services (tier 2 services) or specialist obesity services (tier 3 services). <ul><li>For people with recent-onset type 2 diabetes (diagnosed within a 10-year time frame) with a BMI of 30–34.9 kg/m<sup>2</sup>, consider an assessment for bariatric surgery as long as the person is also receiving or will receive specialist assessment (in a tier 3 service or equivalent).</li><li>If the person is of Asian family origin, consider referral for an assessment for bariatric surgery for people at a lower BMI than other populations as long as they are also receiving or will receive specialist assessment (in a tier 3 service or equivalent).</li></ul></li></ul></li><li><strong>For people with a BMI of 35 kg/m<sup>2</sup> or more (obesity II and obesity III):</strong><ul><li>Offer structured advice regarding <a class="topic-reference internal-reference" href="index.html#advice-on-physical-activity">physical activity</a> and <a class="topic-reference internal-reference" href="index.html#dietary-advice">diet</a>. Consider the use of <a class="topic-reference internal-reference" href="index.html#behavioural-interventions">behavioural interventions</a> to achieve this aim.</li><li>Consider starting <a class="topic-reference internal-reference" href="index.html#drug-treatment">drug treatment</a>.</li><li>Consider the need for <a class="topic-reference internal-reference" href="index.html#bariatric-surgery">bariatric surgery</a>.<ul><li>For people with a BMI of more than 50 kg/m<sup>2</sup>, bariatric surgery is the first-line option (instead of lifestyle intervention or drug treatment) when other interventions have not been effective.</li><li>For people with a BMI of 35–50 kg/m<sup>2</sup>, bariatric surgery is an option if <a class="topic-reference internal-reference" href="index.html#bariatric-surgery">certain criteria</a> are fulfilled.</li><li>For people with recent-onset type 2 diabetes (diagnosed within a 10-year time frame) with a BMI of 35 kg/m<sup>2</sup> or more, offer an expedited assessment for bariatric surgery as long as the person is also receiving or will receive specialist assessment (in a tier 3 service or equivalent).</li><li><a class="topic-reference internal-reference" href="index.html#drug-treatment">Drug treatment</a>  (with orlistat) may be used to maintain or reduce weight before surgery for people who have been recommended surgery as a first-line option, if it is considered that the waiting time for surgery is excessive.</li><li>Local criteria and policies on access to bariatric surgery may vary. Usually<a class="topic-reference internal-reference" href="index.html#referral"> referral</a> for surgery will be made via a specialist obesity management service.</li></ul></li></ul></li><li><strong>Manage any comorbidities that were identified during <a class="topic-reference internal-reference" href="index.html#assessing-a-person-who-is-overweight-or-obese">assessment</a>.</strong><ul><li>Do not delay treatment until the person has lost weight.</li></ul></li><li><strong>Offer additional <a class="topic-reference internal-reference" href="index.html#advice-support">advice and support</a>, as appropriate, including information on treatment targets.</strong><ul><li>Base weight loss targets on the person's comorbidities and risks, rather than weight alone.</li><li>Aim for an overall 5–10% reduction in body weight (or higher [for example more than 20%] in people with BMI of more than 35 kg/m<sup>2</sup>). Weekly weight loss should be no more than 1 kg.</li></ul></li><li><strong>Offer regular, non-discriminatory long-term follow-up by a trained professional.</strong><ul><li>Ensure continuity of care in the multidisciplinary team by good record keeping. </li><li>Document the results of any discussion. Keep a copy of the agreed goals and actions (ensure the person also does this), or put this in their notes.</li></ul></li></ul><!-- end field f9ccc573-a650-4825-95d3-0bc546939708 --><!-- end item 47723b3b-087e-4a2a-b1e5-218552b669d9 --></div><section aria-labelledby="behavioural-interventions" class="ChapterBody-module--wrapper--2HCfk "><h4 id="behavioural-interventions">Behavioural interventions</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9412cb74-21a8-44a3-9c05-918e053396c6 --><!-- begin field 0fc64bb9-b2b2-489e-83a0-96f0958d9170 --><ul><li>Behavioural interventions for adults should include the following strategies, as appropriate for the person:<ul><li>Self-monitoring of behaviour and progress.</li><li>Stimulus control.</li><li>Goal setting.</li><li>Slowing rate of eating.</li><li>Ensuring social support.</li><li>Problem-solving.</li><li>Assertiveness.</li><li>Cognitive restructuring (modifying thoughts).</li><li>Reinforcement of changes.</li><li>Relapse prevention.</li><li>Strategies for dealing with weight regain.</li></ul></li><li>The level of behavioural intervention will depend on the availability of local resources.</li></ul><!-- end field 0fc64bb9-b2b2-489e-83a0-96f0958d9170 --><!-- end item 9412cb74-21a8-44a3-9c05-918e053396c6 --></div></section><section aria-labelledby="basis-for-recommendation-77c" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-77c">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 77c9a88a-da7b-4c18-a340-a84b00a180b0 --><!-- begin field 9e12b201-44f2-4a01-8c38-a84b00a1820f --><p>The recommendations on the management of overweight and obesity are based largely on the National Institute for Health and Care Excellence (NICE) guideline <em>Obesity: identification, assessment and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>]<em> </em>(which replaces section 1.2 in the NICE guideline on <em>Obesity Prevention</em><em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2006a</a>]). For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/cg189/evidence" data-hyperlink-id="562d00cd-937d-4153-8f95-a93100ad0126">full NICE guideline</a>. These recommendations are generally in line with recommendations (and expert opinion) in <a class="topic-reference internal-reference" href="../../have-i-got-the-right-topic/index.html">related NICE guidelines</a>, the Scottish Intercollegiate Guidelines Network (SIGN) guideline on <em>Management of obesity</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2010</a>], and the NHS document <em>Healthy weight, healthy lives: a toolkit for developing local strategies</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FPH, 2008</a>]; several European guidelines, including <em>Pharmacological management of obesity: an endocrine Society clinical practice guideline</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Apovian, 2015</a>], <em>An EASO position statement on multidisciplinary obesity management in adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2014</a>], and the <em>European Guidelines for Obesity Management in Adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>]; international guidelines, including the A<em>merican Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Garvey, 2016</a>], <em>Position of the Academy of Nutrition and Dietetics: Interventions for the Treatment of Overweight and Obesity in Adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Raynor, 2016</a>], <em>Assessment and Lifestyle Management of Patients With Obesity</em> (clinical recommendations from systematic reviews) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kushner, 2014</a>], <em>2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Jensen, 2014</a>], and <em>Recommendations for prevention of weight gain and use of behavioural and pharmacologic interventions to manage overweight and obesity in adults in primary care </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Brauer, 2015</a>]; the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 74, 2017</a>]; and review articles on obesity [<a class="bibliography-reference internal-reference" href="../../references/index.html">Skolnik, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Bray, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">BMJ, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Erlandson, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">McGowan, 2016</a>]. </p><h5>Management of overweight and obesity</h5><ul><li>Experts advise that:<ul><li>A comprehensive obesity management can only be accomplished by a multidisciplinary approach across all levels of care [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">McGowan, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Raynor, 2016</a>]. People who are overweight or obese should be encouraged to engage in a sustainable weight management programme which includes strategies to change behaviour, increase physical activity, and improve diet and eating behaviour [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 74, 2017</a>].</li><li>The management of overweight or obesity should be aimed at modest, sustainable weight loss and maintenance of a healthy weight, to reduce the risk of obesity-related complications [<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 74, 2017</a>]. </li></ul></li><li>There is good evidence that significant clinical benefits may be achieved even by modest weight loss (about 5–10% of initial body weight) and lifestyle modification (improved nutritional content of the diet and modest increases in physical activity and fitness) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>].<ul><li>A 5–15% weight loss over a period of 6 months is realistic and of proven health benefit. A greater (20% or more) weight loss may be considered for those with greater degrees of obesity (body mass index [BMI] of 35 kg/m<sup>2</sup> or more) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>].</li></ul></li></ul><h5>Recommended treatments</h5><ul><li>A systematic review (n = 7788) that aimed to review, describe, and assess currently available approaches to supporting maintenance of weight loss in obese adults found that [<a class="bibliography-reference internal-reference" href="../../references/index.html">Dombrowski, 2014</a>]: <ul><li>Behavioural interventions dealing with diet and physical activity resulted in a small but significant benefit on weight loss maintenance for up to 24 months.</li><li>Drug treatment (with orlistat 120 mg three times daily) resulted in a small but significant benefit on weight loss maintenance for up to 36 months.</li><li>The overall effects of behavioural/lifestyle interventions on weight loss maintenance, with and without drug treatment (orlistat), were small.</li></ul></li><li>Bariatric surgery, where indicated, is the most effective treatment for obesity in terms of long-term weight loss, improvements of comorbidities and quality of life, and decreasing overall mortality [<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">BMJ, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Bray, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Erlandson, 2016</a>].<ul><li>Lifestyle intervention alone (that is diet and exercise) typically produces a modest decrease (5–10%) in body weight over the short term, but the relapse rate can be over 50% depending on the length of the follow-up period [<a class="bibliography-reference internal-reference" href="../../references/index.html">BMJ, 2016</a>].</li><li>Drug treatment plus lifestyle interventions can produce a small but statistically significant increase in weight loss, but long-term maintenance of the weight loss is also poor and adherence to treatment may be affected by possible adverse effects of the medication [<a class="bibliography-reference internal-reference" href="../../references/index.html">BMJ, 2016</a>]. </li></ul></li><li>Expert opinion in the <em>European Guidelines for Obesity Management in Adults </em>is that cognitive behavioural therapy directly addresses behaviours that require change for successful weight loss and weight loss maintenance [<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>].</li></ul><h5>Follow up</h5><ul><li>NICE recommends that a person being managed for overweight or obesity should be offered regular, non-discriminatory long-term follow-up by a trained professional [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>]. </li><li>Expert opinion in the <em>European Guidelines for Obesity Management in Adults</em> is that since obesity is a chronic disease, a follow-up and continued supervision is necessary to prevent weight regain, monitor disease risks, and treat comorbidities [<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>].</li></ul><!-- end field 9e12b201-44f2-4a01-8c38-a84b00a1820f --><!-- end item 77c9a88a-da7b-4c18-a340-a84b00a180b0 --></div></section></section><section aria-labelledby="dietary-advice" class="ChapterBody-module--wrapper--2HCfk "><h3 id="dietary-advice">What advice should I give on diet?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ac6b1ed9-4f29-4aac-a610-aaab1ec39f70 --><!-- begin field e3883aec-594c-4d9b-8ab7-e5d748e70c52 --><ul><li><strong>Advice on dietary changes should take into account the person's food preferences and allow for flexible approaches to reducing calorie intake.</strong><ul><li>Promote a diet which is in line with healthy eating recommendations, acceptable to the person, and sustainable in the long term.</li></ul></li><li><strong>Advise the person to eat a nutritionally balanced diet.</strong><ul><li>This should include:<ul><li>Five portions of a variety of fruit and vegetables each day.</li><li>Meals based on starchy foods (for example bread, pasta, rice, and potatoes) — these should include high fibre varieties if possible.</li><li>Moderate amounts of milk and dairy products — these should be low fat if possible.</li><li>Moderate amounts of protein-rich foods (for example meat, fish, eggs, beans, and lentils).</li></ul></li><li>Also advise the person to:<ul><li>Reduce the consumption of foods high in fat (especially saturated fat), sugar, and salt.</li><li>Cook using methods which reduce fat (for example grilling and steaming).</li><li>Not exceed recommended levels of alcohol, as alcohol is high in calories. Practical ways to limit alcohol consumption may include replacing alcoholic drinks with non-alcoholic, sugar-free drinks and increasing the number of alcohol-free days. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../alcohol-problem-drinking/index.html">Alcohol - problem drinking</a>.</li><li>Improve their diet even if they do not lose weight.</li></ul></li></ul></li><li><strong>Do not use unduly restrictive and nutritionally unbalanced diets, because they are ineffective in the long term and can be harmful.</strong> <ul><li>Diets that are recommended for sustainable weight loss are:<ul><li>Those with a 600 kcal/day deficit (that is, they contain 600 kcal less than the person needs to stay the same weight), <em>or</em></li><li>Those which reduce calories by lowering the fat content (low-fat diets).</li></ul></li><li>Consider low-calorie diets (800–1600 kcal/day), but be aware these are less likely to be nutritionally complete.</li><li>Do not routinely use very-low-calorie diets (800 kcal/day or less) to manage obesity.<ul><li>Only consider these, as part of a multicomponent weight management strategy, for people who are obese and who have a clinically assessed need to rapidly lose weight (for example people who need joint replacement surgery or who are seeking fertility services).</li><li>Ensure that the diet is nutritionally complete, is followed for a maximum of 12 weeks (continuously or intermittently), and that the person following the diet is given ongoing clinical support.</li></ul></li><li>Before starting a person on a very-low-calorie diet as part of a multicomponent weight management strategy:<ul><li>Consider counselling, and assess for eating disorders or other psychopathology to make sure the diet is appropriate for them.</li><li>Discuss the risks and benefits of the diet with the person.</li><li>Explain that it is not a long-term weight management strategy, and that regaining weight may happen and is not because of their own or their doctor's failure.</li><li>Discuss the reintroduction of food following a liquid diet with the person.</li></ul></li><li>Provide a long-term multicomponent strategy to help the person maintain their weight after the use of a very-low-calorie diet.</li><li>Encourage people to eat a balanced diet in the long term, consistent with other healthy eating advice.</li></ul></li><li>The <a href="http://www.htmc.co.uk/resource/data/htmc1/docs/How%20to%20take%20control%20of%20your%20weight.pdf" data-hyperlink-id="d9cb72ab-d740-4653-8cb2-a931009e3aed">'Your Weight, Your Health' </a>booklet produced by the Department of Health is aimed at people who are ready to address their weight, and discusses diet as part of a healthy life.</li></ul><!-- end field e3883aec-594c-4d9b-8ab7-e5d748e70c52 --><!-- end item ac6b1ed9-4f29-4aac-a610-aaab1ec39f70 --></div><section aria-labelledby="basis-for-recommendation-8d3" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-8d3">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 8d3c6cb7-3706-45cd-aead-8d0f6eddf741 --><!-- begin field 800b8370-bf1d-4a06-b678-b5fb87a23547 --><p>The recommendations on the management of overweight and obesity are based largely on the National Institute for Health and Care Excellence (NICE) guideline <em>Obesity: identification, assessment and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>]<em> </em>(which replaces section 1.2 in the NICE guideline on <em>Obesity Prevention</em><em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2006a</a>]). For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/cg189/evidence" data-hyperlink-id="d3a46bde-cacc-42af-9ed4-a93100b47f8d">full NICE guideline</a>. These recommendations are generally in line with recommendations (and expert opinion) in <a class="topic-reference internal-reference" href="../../have-i-got-the-right-topic/index.html">related NICE guidelines</a>, the Scottish Intercollegiate Guidelines Network (SIGN) guideline on <em>Management of obesity</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2010</a>], and the NHS document <em>Healthy weight, healthy lives: a toolkit for developing local strategies</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FPH, 2008</a>]; several European guidelines, including <em>Pharmacological management of obesity: an endocrine Society clinical practice guideline</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Apovian, 2015</a>], <em>An EASO position statement on multidisciplinary obesity management in adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2014</a>], and the <em>European Guidelines for Obesity Management in Adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>]; international guidelines, including the A<em>merican Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Garvey, 2016</a>], <em>Position of the Academy of Nutrition and Dietetics: Interventions for the Treatment of Overweight and Obesity in Adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Raynor, 2016</a>], <em>Assessment and Lifestyle Management of Patients With Obesity</em> (clinical recommendations from systematic reviews) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kushner, 2014</a>], <em>2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Jensen, 2014</a>], and <em>Recommendations for prevention of weight gain and use of behavioural and pharmacologic interventions to manage overweight and obesity in adults in primary care </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Brauer, 2015</a>]; the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 74, 2017</a>]; and review articles on obesity [<a class="bibliography-reference internal-reference" href="../../references/index.html">Skolnik, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Bray, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">BMJ, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Erlandson, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">McGowan, 2016</a>]. </p><p>Specific recommendations on diet are consistent with recommendations in the <a href="https://www.food.gov.uk/sites/default/files/multimedia/pdfs/bghbooklet.pdf" data-hyperlink-id="3ade050b-eb3e-41f2-aadd-a93100b47fa4">Balance of Good Health</a> from the Food Standards Agency. </p><h5>Relationship between dietary fat intake and resulting weight and body fatness</h5><ul><li>A Cochrane systematic review (search date March 2014 to November 2014) assessed the effects of proportion of energy intake from fat on measures of weight and body fatness (including obesity, waist circumference, and body mass index [BMI]) in people not aiming to lose weight. The aim of the review was to understand the relationship between the proportion of energy from fat and resulting weight and body fatness in the general population (32 randomized controlled trials [approximately 54,000 participants] and data from 25 cohorts were included) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Hooper, 2015</a>]. <ul><li>In trials where participants were randomized to a lower fat intake compared with usual or moderate fat intake, but with no intention to reduce weight, there was a consistent, stable, but small effect on body fatness (slightly lower weight, BMI, and waist circumference compared with controls).</li><li>Greater fat reduction and lower baseline fat intake were both associated with greater reductions in weight. However, this effect of reducing total fat was not consistently reflected in cohort studies that assessed the relationship between total fat intake and later measures of body fatness or change in body fatness.</li></ul></li></ul><h5>Optimum diet for weight loss</h5><ul><li>The main focus of dieting is, and has always been, a reduction in calorie intake [<a class="bibliography-reference internal-reference" href="../../references/index.html">BMJ, 2016</a>]. </li><li>Based on available evidence, no single diet has emerged as superior to the others in the long-term [<a class="bibliography-reference internal-reference" href="../../references/index.html">BMJ, 2016</a>]. <ul><li>A meta-analysis (n = 7286) that aimed to determine weight loss outcomes for popular diets found that significant weight loss was observed with any low-carbohydrate or low-fat diet (the weight loss differences between individual, named diets were small). The authors concluded that the result supports the practice of recommending any diet that the person will adhere to in order to lose weight [<a class="bibliography-reference internal-reference" href="../../references/index.html">Johnston, 2014</a>]. </li><li>A second meta-analysis (n = 1797) that compared the effects of low carbohydrate diet with low fat diet on weight and atherosclerotic cardiovascular disease (ASCVD) risk in overweight and obese people found that each diet was associated with significant weight loss and reduction in predicted risk of ASCVD events. Although low carbohydrate diet was associated with modest but significantly greater improvements in weight loss and predicted ASCVD risk in studies from 8 weeks to 24 months in duration, the authors noted that the long-term effects of a low carbohydrate diet require further investigation [<a class="bibliography-reference internal-reference" href="../../references/index.html">Sacker-Bernstein, 2015</a>].</li></ul></li><li>The <em>European Guidelines for Obesity Management in Adults </em>states that a balanced hypocaloric diet results in clinically meaningful weight loss regardless of which macronutrients they emphasise [<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>].</li><li>Expert opinion in a review article is that any diet in which caloric intake is less than caloric expenditure will lead to weight loss. A deficit of at least 500 kcal per day can be achieved with intake of 1200 to 1500 kcal for women and 1500 to 1800 kcal for men [<a class="bibliography-reference internal-reference" href="../../references/index.html">Erlandson, 2016</a>]. </li></ul><!-- end field 800b8370-bf1d-4a06-b678-b5fb87a23547 --><!-- end item 8d3c6cb7-3706-45cd-aead-8d0f6eddf741 --></div></section></section><section aria-labelledby="advice-on-physical-activity" class="ChapterBody-module--wrapper--2HCfk "><h3 id="advice-on-physical-activity">What advice should I give on physical activity?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3f2db586-28e7-4667-b5b7-2ba6bec73955 --><!-- begin field e2bd376a-3716-4b87-9a38-afc1019b204a --><ul><li><strong>When advising on exercise and physical activity, consider the person's:</strong><ul><li>Motivations and goals.</li><li>Current physical fitness and ability.</li><li>Preferences.</li><li>Barriers to being physically active health status (for example a medical condition or a disability).</li></ul></li><li><strong>If appropriate, encourage the person to:</strong><ul><li>Reduce the amount of time they spend being inactive (for example watching television or using a computer).</li><li>Do at least 30 minutes of at least moderate intensity exercise on 5 days a week or more (this can be done in one session or split into a number of sessions each lasting at least 10 minutes); they should build up to these recommended levels. Recommended types of physical activity include:<ul><li>Activities that can be incorporated into everyday life, such as gardening, brisk walking, or cycling. Further recommendations can be found in the National Institute for Health and Care excellence (NICE) guideline on <a href="https://www.nice.org.uk/Guidance/PH41" data-hyperlink-id="3f4876ef-e1ec-42a4-9de5-a93100c8d672">Walking and cycling</a>.</li><li>Supervised exercise programmes. The NICE guideline on <a href="https://www.nice.org.uk/guidance/ph54" data-hyperlink-id="82a8e253-2b7a-40be-a94e-a93100c8d6e2">Exercise referral schemes</a> contains information on the effectiveness and benefits of exercise referral schemes, and makes recommendations on when they should be considered.</li><li>Other activities (for example swimming, aiming to walk a certain number of steps each day, or stair climbing).</li></ul></li><li>Set goals and adjust these as their physical fitness improves.</li></ul></li><li><strong>Advise the person that:</strong><ul><li>They should take more exercise even if it does not lead to weight loss, because exercise has other health benefits, such as reducing the risk of coronary heart disease, stroke, cancer, and type 2 diabetes. It can also help to keep the musculoskeletal system healthy, promote mental wellbeing, and improve life expectancy.</li><li>To prevent obesity, most people may need to do 45–60 minutes of moderate-intensity activity a day, especially if they do not reduce their energy intake. People who have been obese and have lost weight may need to do 60–90 minutes of activity a day to avoid regaining weight.</li><li>A pedometer may be useful for motivation and to help monitor their activity levels. If appropriate, they can gradually work towards a goal of 10,000 steps a day.</li></ul></li><li>The <a href="http://www.htmc.co.uk/resource/data/htmc1/docs/How%20to%20take%20control%20of%20your%20weight.pdf" data-hyperlink-id="d22cf4a5-ef4b-4de4-a99a-a93100c8d6fa">'Your Weight, Your Health' </a>booklet produced by the Department of Health is aimed at people who are ready to address their weight, and discusses incorporating exercise into a healthy life.</li></ul><p> </p><!-- end field e2bd376a-3716-4b87-9a38-afc1019b204a --><!-- end item 3f2db586-28e7-4667-b5b7-2ba6bec73955 --></div><section aria-labelledby="basis-for-recommendation-b88" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-b88">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item b881056a-d729-47cf-a2e5-299842cc52da --><!-- begin field 469ef31a-0be3-4da6-8e47-6d627333f3f9 --><p>The recommendations on the management of overweight and obesity are based largely on the National Institute for Health and Care Excellence (NICE) guideline <em>Obesity: identification, assessment and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>]<em> </em>(which replaces section 1.2 in the NICE guideline on <em>Obesity Prevention</em><em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2006a</a>]). For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/cg189/evidence" data-hyperlink-id="aa517462-14b3-4e9e-950d-a931009e655f">full NICE guideline</a>. These recommendations are generally in line with recommendations (and expert opinion) in <a class="topic-reference internal-reference" href="../../have-i-got-the-right-topic/index.html">related NICE guidelines</a>, the Scottish Intercollegiate Guidelines Network (SIGN) guideline on <em>Management of obesity</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2010</a>], and the NHS document <em>Healthy weight, healthy lives: a toolkit for developing local strategies</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FPH, 2008</a>]; several European guidelines, including <em>Pharmacological management of obesity: an endocrine Society clinical practice guideline</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Apovian, 2015</a>], <em>An EASO position statement on multidisciplinary obesity management in adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2014</a>], and the <em>European Guidelines for Obesity Management in Adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>]; international guidelines, including the A<em>merican Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Garvey, 2016</a>], <em>Position of the Academy of Nutrition and Dietetics: Interventions for the Treatment of Overweight and Obesity in Adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Raynor, 2016</a>], <em>Assessment and Lifestyle Management of Patients With Obesity</em> (clinical recommendations from systematic reviews) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kushner, 2014</a>], <em>2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Jensen, 2014</a>], and <em>Recommendations for prevention of weight gain and use of behavioural and pharmacologic interventions to manage overweight and obesity in adults in primary care </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Brauer, 2015</a>]; the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 74, 2017</a>]; and review articles on obesity [<a class="bibliography-reference internal-reference" href="../../references/index.html">Skolnik, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Bray, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">BMJ, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Erlandson, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">McGowan, 2016</a>]. </p><p>Specific recommendations on physical activity are consistent with the current <a href="https://www.gov.uk/government/publications/uk-physical-activity-guidelines" data-hyperlink-id="52a3f507-10da-4e7e-909f-a931009e6568">UK physical activity guidelines</a> (available on <a href="https://www.gov.uk/" data-hyperlink-id="6547fd89-7f88-4a7f-b6f9-a931009e656d">www.gov.uk</a>).</p><!-- end field 469ef31a-0be3-4da6-8e47-6d627333f3f9 --><!-- end item b881056a-d729-47cf-a2e5-299842cc52da --></div></section></section><section aria-labelledby="drug-treatment" class="ChapterBody-module--wrapper--2HCfk "><h3 id="drug-treatment">What do I need to know about drug treatment for people who are overweight or obese?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 0047ad40-ae47-438f-8ad1-a84b008f1f65 --><!-- begin field 17d42bc4-d9bf-4860-aad1-a84b008f20ec --><ul><li><strong>The decision to start drug treatment should be made after discussing the potential benefits and limitations with the person, including the mode of action, adverse effects, monitoring requirements, and the potential impact on the person's motivation.</strong><ul><li>Drug treatment should:<ul><li>Only be considered once dietary and physical activity interventions have been evaluated.</li><li>Form part of an integrated approach to weight management, which should include advice, support, counselling on diet and physical activity, and behavioural strategies.</li></ul></li><li>Make arrangements for appropriate healthcare professionals to offer information, support, and counselling on additional diet, physical activity, and behavioural strategies when drug treatment is prescribed.</li><li>Provide information on patient support programmes. </li><li>Monitor the effect of drug treatment, and reinforce lifestyle advice and adherence through regular review. </li></ul></li><li><strong>Orlistat </strong>is licensed, in conjunction with a mildly hypocaloric diet, for adults aged between 18–75 years who meet one of the following criteria: obese with a body mass index (BMI) of 30 kg/m<sup>2 </sup>or more, or<em> </em>overweight with a BMI of 28 kg/m<sup>2</sup> or more with associated risk factors. <ul><li>The recommended dose of orlistat is one 120 mg capsule taken with water immediately before, during, or up to one hour after each main meal. If a meal is missed or contains no fat, the dose of orlistat should be omitted.<ul><li>Orlistat 60 mg capsules (Alli®) can be purchased over-the-counter from pharmacies and does not require a prescription. </li></ul></li><li>Discontinue treatment with orlistat after 12 weeks if the person has not lost at least 5% of their body weight (as measured at the start of drug treatment).<ul><li>Rates of weight loss may be slower in people with type 2 diabetes, so less strict goals (for example a loss of more than 3% of their body weight in 12 weeks) may be appropriate.</li><li>These goals should be agreed with the person and reviewed regularly.</li></ul></li><li>For people who have lost the recommended amount of weight, there is no restriction on how long orlistat may be prescribed. The decision to continue treatment should be made on an individual basis, taking into account the benefits, risks, and cost of treatment. This should be reviewed at regular intervals.</li><li>See the section on <a class="topic-reference internal-reference" href="../../prescribing-information/index.html">Prescribing information</a> for information on the contraindications, cautions, adverse effects, and possible drug interactions of orlistat.</li></ul></li><li><strong>Liraglutide (Saxenda®) </strong>is licensed as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with an initial BMI of 30 kg/m<sup>2</sup> or more (obese), or from 27 kg/m<sup>2</sup> to less than 30 kg/m<sup>2</sup> (overweight) in the presence of at least one weight-related comorbidity, such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea.<ul><li>Liraglutide (Saxenda®) is a Black Triangle drug and is subject to additional monitoring by the Medicines and Healthcare products Regulatory Agency (MHRA).</li><li>Consider referral to specialist obesity services if this treatment is being considered. </li><li>Treatment should be discontinued after 12 weeks if the person has not lost at least 5% of their initial body weight.</li></ul></li></ul><!-- end field 17d42bc4-d9bf-4860-aad1-a84b008f20ec --><!-- end item 0047ad40-ae47-438f-8ad1-a84b008f1f65 --></div><section aria-labelledby="basis-for-recommendation-9b2" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-9b2">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9b2ba648-8eec-4717-a2ff-a84b008f20f7 --><!-- begin field 4a55c416-7d82-4fa4-a58c-a84b008f20f7 --><p>The recommendations on the management of overweight and obesity are based largely on the National Institute for Health and Care Excellence (NICE) guideline <em>Obesity: identification, assessment and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>]<em> </em>(which replaces section 1.2 in the NICE guideline on <em>Obesity Prevention</em><em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2006a</a>]). For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/cg189/evidence" data-hyperlink-id="0a3da9f7-e47b-4bda-81b8-a93100a836d6">full NICE guideline</a>. These recommendations are generally in line with recommendations (and expert opinion) in <a class="topic-reference internal-reference" href="../../have-i-got-the-right-topic/index.html">related NICE guidelines</a>, the Scottish Intercollegiate Guidelines Network (SIGN) guideline on <em>Management of obesity</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2010</a>], and the NHS document <em>Healthy weight, healthy lives: a toolkit for developing local strategies</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FPH, 2008</a>]; several European guidelines, including <em>Pharmacological management of obesity: an endocrine Society clinical practice guideline</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Apovian, 2015</a>], <em>An EASO position statement on multidisciplinary obesity management in adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2014</a>], and the <em>European Guidelines for Obesity Management in Adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>]; international guidelines, including the A<em>merican Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Garvey, 2016</a>], <em>Position of the Academy of Nutrition and Dietetics: Interventions for the Treatment of Overweight and Obesity in Adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Raynor, 2016</a>], <em>Assessment and Lifestyle Management of Patients With Obesity</em> (clinical recommendations from systematic reviews) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kushner, 2014</a>], <em>2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Jensen, 2014</a>], and <em>Recommendations for prevention of weight gain and use of behavioural and pharmacologic interventions to manage overweight and obesity in adults in primary care </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Brauer, 2015</a>]; the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 74, 2017</a>]; and review articles on obesity [<a class="bibliography-reference internal-reference" href="../../references/index.html">Skolnik, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Bray, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">BMJ, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Erlandson, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">McGowan, 2016</a>]. </p><h5>Available drug treatments</h5><ul><li>There are currently 2 licensed pharmacological treatments for weight management available in the UK.<ul><li>Orlistat is a pancreatic lipase inhibitor that inhibits triglyceride digestion and reduces the absorption of dietary fat [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017a</a>]. </li><li>Liraglutide (Saxenda®), a glucagon-like peptide-1 (GLP-1) receptor antagonist, received a European marketing authorisation for obesity treatment in March 2015 and was launched in the UK in January 2017 [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2017</a>].<ul><li>Liraglutide (Victoza®) has been licensed in the UK for the treatment of type 2 diabetes in adults since 2009. However, it is not licensed as a pharmacological treatment option for weight management [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2017</a>]. </li></ul></li></ul></li><li>The recommendation to consider referral to specialist obesity services if treatment with liraglutide (Saxenda®) is being considered is based on what CKS considers to be good clinical practice.</li></ul><h5>Efficacy of drug treatments</h5><ul><li>Drug treatment can be a useful addition to lifestyle change for people who have been unsuccessful with diet and exercise alone [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Yanovski, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Apovian, 2015</a>]. <ul><li>A  systematic review and meta-analysis (n = 29,018) that compared weight loss and adverse events among drug treatments for obesity in overweight and obese adults found that compared with placebo, orlistat, liraglutide, and other treatments not licensed for use in the UK (lorcaserin, naltrexone-bupropion, and phentermine-topiramate) were all associated with achieving at least 5% weight loss at 52 weeks. Liraglutide and phentermine-topiramate were associated with the highest odds of achieving at least 5% weight loss [<a class="bibliography-reference internal-reference" href="../../references/index.html">Khera, 2016</a>].</li><li>A systematic review (n = 7788) that aimed to review, describe, and assess currently available approaches to supporting maintenance of weight loss in obese adults found that treatment with orlistat 120 mg three times daily showed a small but significant benefit on weight loss maintenance for up to 36 months [<a class="bibliography-reference internal-reference" href="../../references/index.html">Dombrowski, 2014</a>]. </li></ul></li></ul><h5>When to discontinue drug treatment</h5><ul><li>The recommendation to discontinue treatment in people who do not respond with weight loss of at least 5% is based on the manufacturers' Summaries of Product Characteristics (SPCs) for Xenical® and Saxenda® [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017b</a>]. Discontinuing treatment in people who do not respond with weight loss of at least 5% decreases the person's exposure to the risks and costs of drug treatment when there is little prospect of long-term benefit [<a class="bibliography-reference internal-reference" href="../../references/index.html">Yanovski, 2014</a>]. </li><li>The NICE guideline highlights that rates of weight loss may be slower in people with type 2 diabetes, so less strict goals may be appropriate [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>]. The <em>European Guidelines for Obesity Management in Adults </em>suggests a loss of more than 3% in this group of people [<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>].</li></ul><!-- end field 4a55c416-7d82-4fa4-a58c-a84b008f20f7 --><!-- end item 9b2ba648-8eec-4717-a2ff-a84b008f20f7 --></div></section></section><section aria-labelledby="bariatric-surgery" class="ChapterBody-module--wrapper--2HCfk "><h3 id="bariatric-surgery">What do I need to know about bariatric surgery?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ec26c08f-ece7-44df-8b18-a84b008f40d6 --><!-- begin field bf060967-1838-4ab6-b7cd-a84b008f4274 --><ul><li><strong>Bariatric surgery is recommended as a treatment option if <em>all</em> of the following criteria are fulfilled:</strong><ul><li>The person has a body mass index (BMI) of 40 kg/m<sup>2 </sup>or more, or between 35 kg/m<sup>2</sup> and 40 kg/m<sup>2</sup> with other significant disease that could be improved if they lost weight, for example type 2 diabetes, hypertension, or severe mobility problems.</li><li>All appropriate non-surgical measures have been tried but the person has not achieved or maintained adequate, clinically beneficial weight loss.</li><li>The person has been receiving or will receive intensive management in a tier 3 service.</li><li>The person is generally fit for anaesthesia and surgery.</li><li>The person commits to the need for long-term follow up</li></ul></li><li><strong>In addition to the criteria listed above, </strong>bariatric surgery is the option of choice (instead of lifestyle interventions or drug treatment) for adults with a BMI of more than 50 kg/m<sup>2</sup> when other interventions have not been effective. <ul><li><a class="topic-reference internal-reference" href="index.html#drug-treatment">Drug treatment</a> (with orlistat) may be used to maintain or reduce weight before surgery for people who have been recommended surgery as a first-line option, if it is considered that the waiting time for surgery is excessive.</li></ul></li><li><strong>For people with recent-onset type 2 diabetes (diagnosed within a 10-year time frame):</strong><ul><li>If BMI is 35 kg/m<sup>2</sup> or over, offer an expedited assessment for bariatric surgery as long as the person is also receiving or will receive specialist assessment (in a tier 3 service or equivalent).</li><li>If BMI is 30–34.9 kg/m<sup>2</sup>, consider an assessment for bariatric surgery as long as the person is also receiving or will receive specialist assessment (in a tier 3 service or equivalent).</li><li>If the person is of Asian family origin, consider an assessment for bariatric surgery for people at a lower BMI than other populations as long as they are also receiving or will receive specialist assessment (in a tier 3 service or equivalent).</li></ul></li></ul><!-- end field bf060967-1838-4ab6-b7cd-a84b008f4274 --><!-- end item ec26c08f-ece7-44df-8b18-a84b008f40d6 --></div><section aria-labelledby="basis-for-recommendation-e36" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-e36">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e369822a-26b3-4108-b780-a84b008f427e --><!-- begin field ca7db841-6ee8-4a2e-aec6-a84b008f427e --><p>The recommendations on the management of overweight and obesity are based largely on the National Institute for Health and Care Excellence (NICE) guideline <em>Obesity: identification, assessment and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>]<em> </em>(which replaces section 1.2 in the NICE guideline on <em>Obesity Prevention</em><em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2006a</a>]). For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/cg189/evidence" data-hyperlink-id="26b721f3-b955-47f8-99c5-a93100a8f2ca">full NICE guideline</a>. These recommendations are generally in line with recommendations (and expert opinion) in <a class="topic-reference internal-reference" href="../../have-i-got-the-right-topic/index.html">related NICE guidelines</a>, the Scottish Intercollegiate Guidelines Network (SIGN) guideline on <em>Management of obesity</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2010</a>], and the NHS document <em>Healthy weight, healthy lives: a toolkit for developing local strategies</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FPH, 2008</a>]; several European guidelines, including <em>Pharmacological management of obesity: an endocrine Society clinical practice guideline</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Apovian, 2015</a>], <em>An EASO position statement on multidisciplinary obesity management in adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2014</a>], and the <em>European Guidelines for Obesity Management in Adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>]; international guidelines, including the A<em>merican Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Garvey, 2016</a>], <em>Position of the Academy of Nutrition and Dietetics: Interventions for the Treatment of Overweight and Obesity in Adults </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Raynor, 2016</a>], <em>Assessment and Lifestyle Management of Patients With Obesity</em> (clinical recommendations from systematic reviews) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kushner, 2014</a>], <em>2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Jensen, 2014</a>], and <em>Recommendations for prevention of weight gain and use of behavioural and pharmacologic interventions to manage overweight and obesity in adults in primary care </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Brauer, 2015</a>]; the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 74, 2017</a>]; and review articles on obesity [<a class="bibliography-reference internal-reference" href="../../references/index.html">Skolnik, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Bray, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">BMJ, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Erlandson, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">McGowan, 2016</a>]. </p><ul><li>In general, bariatric surgery reduces calorie intake by altering hunger and fullness through changes to the stomach and/or small intestine [<a class="bibliography-reference internal-reference" href="../../references/index.html">BMJ, 2016</a>].</li><li>Bariatric surgery, where indicated, is the most effective treatment for morbid obesity in terms of long-term weight loss, improvements of comorbidities and quality of life, and decreasing overall mortality [<a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Yumuk, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">BMJ, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Bray, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Erlandson, 2016</a>].</li><li>A Cochrane systematic review (search date November 2013) assessed the effects of bariatric surgery for overweight and obesity, including the control of comorbidities, in 1798 participants and found that surgery results in greater improvement in weight loss outcomes and weight associated comorbidities compared with non-surgical interventions, regardless of the type of procedures used [<a class="bibliography-reference internal-reference" href="../../references/index.html">Colquitt, 2014</a>].</li></ul><!-- end field ca7db841-6ee8-4a2e-aec6-a84b008f427e --><!-- end item e369822a-26b3-4108-b780-a84b008f427e --></div></section></section><section aria-labelledby="referral" class="ChapterBody-module--wrapper--2HCfk "><h3 id="referral">When should I consider referring people who are overweight or obese?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ac433cb6-0f75-4bd9-8faa-a84900c4ea77 --><!-- begin field e03d106b-482e-4205-a368-a84900c4ee4b --><ul><li><strong>Consider referral for lifestyle weight management services (tier 2 services)</strong> for people with a body mass index (BMI) of 30 kg/m<sup>2</sup> or more.<ul><li>Consider referral from a lower BMI (for example 27.5kg/m<sup>2</sup> or more) for people of black African, African-Caribbean, and Asian family origin, as they are at increased risk of <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a>  at a lower BMI.</li><li>Where there is capacity, it is recommended that these services are available for people with a BMI of 25 kg/m<sup>2</sup> or more (23 kg/m<sup>2</sup> or more for those of black African, African-Caribbean, and Asian family origin).</li><li>Where local provision is not available, consider directing to commercial services which adhere to the National Institute for Health and Care Excellence (NICE) guidance on <a href="https://www.nice.org.uk/guidance/ph53/chapter/6-Related-NICE-guidance" data-hyperlink-id="5bf71ed6-c93e-4d01-b3b9-a93100b32ae2">Weight management: lifestyle services for overweight or obese adults</a>.</li></ul></li><li><strong>Consider referral to a specialist obesity service (tier 3 services) if:</strong><ul><li>The underlying causes of overweight and obesity need to be assessed.</li><li>The person has complex disease states or needs that cannot be managed adequately in tier 2 (for example, the additional support needs of people with learning disabilities).</li><li>Conventional treatment has failed in primary or secondary care.</li><li>Drug treatment is being considered for a person with a BMI of more than 50 kg/m<sup>2</sup>.</li><li>Specialist interventions (such as a very-low-calorie diet) may be needed. </li><li>Surgery is being considered.</li><li>Treatment with liraglutide (Saxenda®) is being considered.</li></ul></li><li><strong>For people with recent-onset type 2 diabetes (diagnosed within a 10-year time frame):</strong><ul><li>If BMI is 35 kg/m<sup>2</sup> or over, offer an expedited assessment for bariatric surgery as long as the person is also receiving or will receive specialist assessment (in a tier 3 service or equivalent).</li><li>If BMI is 30–34.9 kg/m<sup>2</sup>, consider an assessment for bariatric surgery as long as the person is also receiving or will receive specialist assessment (in a tier 3 service or equivalent).</li><li>If the person is of Asian family origin, consider an assessment for bariatric surgery for people at a lower BMI than other populations as long as they are also receiving or will receive specialist assessment (in a tier 3 service or equivalent).</li></ul></li><li><strong>It is important to be familiar with local services as referral criteria may vary locally.</strong></li></ul><!-- end field e03d106b-482e-4205-a368-a84900c4ee4b --><!-- end item ac433cb6-0f75-4bd9-8faa-a84900c4ea77 --></div><section aria-labelledby="basis-for-recommendation-2dc" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-2dc">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2dc8a215-3af6-4dce-980f-a84900c4eede --><!-- begin field 83f35e3a-a3a2-4a03-b506-a84900c4eede --><h5>Referral for tier 2 services</h5><ul><li>The recommendations on when to consider referring for tier 2 services are based on t he Public Health England (PHE) guidance on <a href="https://www.gov.uk/government/publications/adult-weight-management-a-guide-to-brief-interventions" data-hyperlink-id="a0ef8c69-1c7d-459e-9678-a93100b349ff">Adult weight management: a guide to brief interventions</a> [<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2017</a>].</li></ul><h5>Referral for tier 3 services</h5><ul><li>The recommendations on when to consider referring for tier 3 services are based largely on the National Institute for Health and Care Excellence (NICE) guideline <em>Obesity: identification, assessment and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>]<em> </em>(which replaces section 1.2 in the NICE guideline on <em>Obesity Prevention</em><em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2006a</a>]). For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/cg189/evidence" data-hyperlink-id="6e891df4-5e01-483b-9d18-a93100b34b0e">full NICE guideline</a>. <ul><li>The NHS England report on <a href="http://www.england.nhs.uk/wp-content/uploads/2014/03/owg-join-clinc-path.pdf" data-hyperlink-id="7706cadc-57b2-4088-87fd-a93100b34b13">Joined up clinical pathways for obesity</a> also has more information on tier 3 services.</li></ul></li><li>The recommendation to consider referral to specialist obesity services if treatment with liraglutide (Saxenda®) is being considered is based on what CKS considers to be good clinical practice.</li></ul><h5>Referral for people with recent-onset type 2 diabetes</h5><ul><li>The recommendations on when to consider referring people with recent-onset type 2 diabetes (diagnosed within a 10-year time frame) is based on the NICE guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>].</li></ul><!-- end field 83f35e3a-a3a2-4a03-b506-a84900c4eede --><!-- end item 2dc8a215-3af6-4dce-980f-a84900c4eede --></div></section></section><section aria-labelledby="advice-support" class="ChapterBody-module--wrapper--2HCfk "><h3 id="advice-support">How should I advise and support a person who is overweight or obese?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e1aa52ab-a747-4585-a061-a84d00c47070 --><!-- begin field abff06a2-b393-4279-bfde-a84d00c47404 --><ul><li><strong>Offer a level of support appropriate to the person's needs.</strong><ul><li>Provide information in formats and languages that are suited to the person.</li><li>Use everyday, jargon-free language and explain any technical terms when talking to the person and their family or carers.</li><li>Take into account the person's age and stage of life, gender, cultural needs and sensitivities, ethnicity, social and economic circumstances, and specific communication needs (for example because of due to learning disabilities, physical disabilities, or cognitive impairments due to neurological conditions).</li><li>Offer encouragement and praise for successes, however small.</li></ul></li><li><strong>Advise the person on the aims and benefits of treatment.</strong><ul><li>The aim of management is for an overall 5–10% reduction in body weight (or higher [for example more than 20%] in people with body mass index [BMI] of more than 35 kg/m<sup>2</sup>); weekly weight loss should be no more than 1 kg.</li><li>Explain the <a class="topic-reference internal-reference" href="../../background-information/prognosis/index.html">benefits</a> of modest weight loss with regard to comorbidities and disease risk, particularly if the person is obese.</li><li>Discuss why gaining more weight may increase <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">risks to health</a>.</li><li>Explain why excess weight can be problematic in terms of comorbidities and the chance of developing <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a>.</li></ul></li><li><strong>Remind the person of the need for long-term behavioural changes, including adherence to advice on <a class="topic-reference internal-reference" href="index.html#dietary-advice">diet</a><strong> </strong> and <a class="topic-reference internal-reference" href="index.html#advice-on-physical-activity">physical activity</a>.</strong><ul><li>Explain the distinction between losing weight and maintaining weight loss, and the importance of developing skills for both. Advise that the change from losing weight to maintenance typically happens after 6–9 months of treatment.</li><li>Advise that weight cycling, defined by repeated loss and regain of body weight, may be linked to increased risk for hypertension, dyslipidaemia, gallbladder disease, psychological distress, and depression.</li><li>Explain that physical activity alone without dietary changes are not effective for weight loss.</li></ul></li><li><strong>For people who have been prescribed <a class="topic-reference internal-reference" href="../../prescribing-information/orlistat/index.html">orlistat</a>, advise that:</strong><ul><li>Orlistat 120 mg should be taken immediately before, during, or up to 1 hour after each main meal (up to a maximum of three times a day).</li><li>The dose of orlistat should be omitted if a meal is missed or if the meal contains little or no fat.</li><li>They should stop taking orlistat and seek medical assistance if they develop symptoms of hepatitis (yellowing skin and eyes, itching, dark-coloured urine, stomach pain and liver tenderness). See the section on <a class="topic-reference internal-reference" href="../../prescribing-information/orlistat/index.html#adverse-effects">Adverse effects</a> for more information.</li></ul></li><li><strong>For people being considered for <a class="topic-reference internal-reference" href="index.html#bariatric-surgery">bariatric surgery</a>,</strong> provide appropriate information on the procedure, including the risks, benefits, and long-term efficacy.<ul><li>NHS Choices has useful information on <a data-hyperlink-id="15efadbb-7713-4c2f-a609-a93100c141dc" href="https://www.nhs.uk/conditions/weight-loss-surgery/">Weight loss surgery</a>.</li></ul></li><li><strong>Provide additional patient information on overweight and obesity. </strong><ul><li>NHS A-Z has useful information on <a data-hyperlink-id="84da92d1-d878-4ec8-b213-a93100c1427b" href="https://www.nhs.uk/conditions/obesity/">Obesity</a>.</li><li>The <a data-hyperlink-id="b4172681-c8be-41f7-b2af-a93100c14281" href="http://www.htmc.co.uk/resource/data/htmc1/docs/How%20to%20take%20control%20of%20your%20weight.pdf">'Your Weight, Your Health' </a>booklet produced by the Department of Health is aimed at people who are ready to address their weight, and discusses incorporating diet and exercise into a healthy life.</li></ul></li><li><strong>Give information on voluntary organisations and support groups and how to contact them. </strong><ul><li>Examples include <a data-hyperlink-id="2122db9f-be0d-4c43-be40-a93100c1428e" href="https://www.britishobesitysociety.org/contact-us">British Obesity Society (BOS)</a>, <a data-hyperlink-id="b6e651b4-d678-4106-9df5-a93100c1445f" href="http://hoopuk.org.uk/contact-2/">HOOP UK</a>, and <a data-hyperlink-id="56a5b796-9168-4eb3-8183-a93100c145d6" href="http://www.weightconcern.org.uk/node/15">Weight Concern</a>.</li></ul></li></ul><!-- end field abff06a2-b393-4279-bfde-a84d00c47404 --><!-- end item e1aa52ab-a747-4585-a061-a84d00c47070 --></div><section aria-labelledby="basis-for-recommendation-822" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-822">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 822d8102-bccd-4334-97ec-a84d00c47487 --><!-- begin field 00a6cc6a-53e5-45ca-b8b0-a84d00c47487 --><p>These recommendations are based largely on the National Institute for Health and Care Excellence (NICE) guideline <em>Obesity: identification, assessment and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>] (which replaces section 1.2 in the NICE guideline on <em>Obesity Prevention</em><em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2006a</a>]). For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/cg189/evidence" data-hyperlink-id="ad0fa7ee-2651-4fbd-bfde-a93100c1ee67">full NICE guideline</a>. The advice for people who have been prescribed orlistat is based on information in the manufacturer's Summary of Product Characteristics (SPC) [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017a</a>].</p><!-- end field 00a6cc6a-53e5-45ca-b8b0-a84d00c47487 --><!-- end item 822d8102-bccd-4334-97ec-a84d00c47487 --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/obesity/management/management/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>